minute to learn about health care negotiations highlights
minute to learn about health care negotiations highlights
2021 National Health Insurance Drug Catalog Adjustment Results:
December 3, 2021, the National Medical Security Administration held a press conference to announce the results of the 2021 national medical insurance drug catalog adjustment, this year's catalog adjustment work has finally settled. In terms of quantity, a total of 74 drugs were added to the list and 11 drugs were transferred out of the list. Judging from the negotiation situation, a total of 117 drugs were negotiated, and 94 were successfully negotiated, with an overall success rate of 80.34. Among them, 67 of the 85 exclusive drugs outside the catalogue were negotiated, with a success rate of 78.82 and an average price reduction of 67.71. After the adjustment, the total number of drugs in the national medical insurance drug list is 2860, including 1486 western medicines and 1374 proprietary Chinese medicines. There are still 892 kinds of Chinese herbal medicines. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2022.
Noxinasan Sodium: From "Sky Price" to Floor
health insurance negotiations is the inclusion of Noxinasan sodium, a high-priced drug for the treatment of spinal muscular atrophy (SMA) under Bojian. SMA is a genetic orphan disease, called spinal muscular atrophy in Chinese. The incidence rate of newborns is about one in ten thousand. At present, there are about 30000 to 50000 SMA patients in China. Due to the high cost of research and development and the small audience, the price of orphan diseases is generally set very high. The original price of Noxinasan sodium was once as high as 700000 RMB/branch, and one injection could not be cured, requiring continuous medication, with an annual cost of about 2.1 million. At present, after being included in medical insurance, it will not exceed 33000 yuan/branch and can be reimbursed.
drug multi-point flowering
, another hot spot in this medical insurance negotiation is that a total of 7 rare disease drugs, including Nuoxinasheng sodium injection, are included in the medical insurance catalog. It can be seen that the national medical insurance fund is "basic" at the same time, for a small number of people. The attention to drug demands has increased unabated.
List of 7 New Rare Disease Drugs
three domestic PD-1 new indications are selected
star product PD-1 is still full of topics. At present, four domestic PD-1 products have been included in health insurance, the health insurance negotiations are mainly around the new indications. In the end, Cinda, Junshi and Baiji Shenzhou's PD-1 new indications all entered, Hengrui's PD-1 this year's new nasopharyngeal cancer two indications did not enter, but its company's main indications have been included in health insurance, the impact is small.
worth mentioning that Mercadon's pembrolizumab injection (drug K) and Bristol-Myers Squibb's nivolumab (drug O) have not been covered by medical insurance again, AstraZeneca's drug I also did not appear, and imported PD-(L)1 was completely wiped out.
With the wider indications of domestic PD-1 into health insurance, it means that more patients can get treatment at low cost. Domestic PD-1 pharmaceutical companies will also further increase their market share, which is also one of the effective strategies for domestic biopharmaceutical companies to catch up and occupy the market.
domestic ADC drugs included in health insurance for the first time
Antibody Conjugate Drug (ADC) is a kind of potent anticancer drug targeting cancer cells by coupling monoclonal antibodies and potent and highly toxic small molecules through biologically active linkers, which has attracted much attention in the industry.
Rongchang biological development of vidicetuzumab is the first domestic ADC drugs, June 9 this year officially approved for the treatment of gastric cancer. In the preliminary list, only Takeda's Vibutuximab and Rongchang Bio's Vidicetuzumab were shortlisted for ADC drugs. Roche's enmetrastuzumab was not on the initial list and was not listed in the 2020 Medicare catalog.
on the basis of the national medical reform policy and the vast market of patients, Chinese biopharmaceutical companies are entering the fast lane of development,cater to the big wave of medical reform, stand out from the crowded R & D track, and quickly realize the commercialization of products is the focus of the development of enterprises, which also requires upstream bioprocess service providers to go further, the need for better quality, more professional technology to ensure the safety and effectiveness of drugs.
